NOVARTIS AG

NVS · XNYS

CIK 1114448fmd_1C3HJXRB6Y25MAN3NKQWDR0S2HManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2015 to Dec 31, 2025, 21 periods

Income Statement · Annual · Millions · USD
Line item	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Cost of revenue	17,520	13,633	14,510	14,425	15,121	11,735	11,582	12,472	12,827	13,699
Gross profit	31,916	29,771	31,589	34,252	34,777	32,239	31,879	34,188	38,895	42,975
Research and development	9,039	8,389	8,489	9,402	8,980	8,641	9,172	11,371	10,022	11,200
Selling, general and administrative	14,192	12,465	13,717	14,369	14,197	12,827	12,193	12,517	12,566	13,248
Operating income	8,268	8,702	8,403	9,086	10,152	10,056	7,946	9,769	14,544	17,644
Interest expense	707	750	932	850	869	787	800	855	1,006	1,144
Income before taxes	7,817	9,102	14,095	8,940	9,878	24,530	7,177	9,123	13,640	16,352
Income tax expense	1,119	1,603	1,295	1,793	1,807	1,625	1,128	551	1,701	2,385
Net income from continuing operations	6,698	7,499	12,800	7,147	8,071	22,905	6,049	8,572	11,939	13,967
Net income	6,712	7,703	12,611	11,732	8,072	24,021	6,955	14,850	11,941	13,984